As Sanofi's SERD falls, Menarini’s advances with EU review

Just days ago, Sanofi sent its oral selective estrogen receptor degrader (SERD) for breast cancer to the trash can. But over in Italy, a small biotech is plodding forward with its own candidate, with the EU beginning a regulatory review.